- SULFONAMIDE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY
-
The present invention provides an sulfonamide derivative having DP receptor antagonistic activity and a pharmaceutical composition comprising the said compound as an active ingredient, and further a therapeutic agent for treating allergic diseases. A comp
- -
-
-
- N-PHENYL-N'-PHENYLSULFONYLPIPERAZINE DERIVATIVE AND METHOD FOR PRODUCING INTERMEDIATE FOR SAME
-
The present invention provides the salt and the crystal thereof of 2-(oxazole-2-yl)phenol derivative which are the intermediate in the process of producing N-phenyl-N'-phenylsulfonyl piperazine derivative, and the process of producing the salt as well as the process of producing N-phenyl-N'-phenylsulfonyl piperazine derivative through the salt. A method of producing the salt and the crystal thereof of the compound represented by Formula(I): wherein X is halogen; and the process of producing the salt as well as the process of producing N-phenyl-N'-phenylsulfonyl piperazine derivative through the salt.
- -
-
-
- SULFONAMIDE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY
-
A sulfonamide derivative having DP receptor antagonistic activity; and a medicinal composition and a therapeutic agent for allergic diseases which each contains the compound as an active ingredient. The derivative is a compound represented by the general formula (II): (II) (wherein ring A is an aromatic carbocycle, etc.; ring B is a nitrogenous nonaromatic heterocycle, etc.; ring C is an aromatic carbocycle, etc.; R1 is carboxy, etc.; R2's each independently is halogeno, etc.; R3 is optionally substituted alkyloxy, etc.; R4's each independently is halogeno, etc.; R5's each independently is optionally substituted alkyl, etc.; M is sulfonyl, etc.; Y is a single bond, etc.; L1 is a single bond, etc.; L2 is a single bond, etc.; k is 0, 1, 2, 3, or 4; n is 0, 1, or 2; and q is 0, 1, 2, or 3, provided that, for example, a) when ring B is a 6-membered nitrogenous heterocycle containing one or two nitrogen atoms and ring C is a benzene ring, then k is not 0), a pharmaceutically acceptable salt of the compound, or a hydrate of either.
- -
-
Page/Page column 136; 169
(2010/11/26)
-